AVROBIO Receives Orphan-Drug Designation from the FDA for AVR‑RD‑02 for the Treatment of Gaucher…
AVROBIO announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of…
Read More...
Read More...
